BRCA1 and breast carcinoma: Breast carcinoma in the CSbbph-low group that corresponds to a CSddrm-low immunophenotype has a 95% 10-year rate, but the ten-year DSS rate of breast carcinoma with a BRCA1+/BRCA2+/PARP1+/γH2AX+ immunophenotype was 35% [14].